Warfarin and atrial fibrillation: From ideal to real the warfarin affaire

Thrombosis Journal

Volumn 12, Issue 1, 2014, Pages

  Molteni, Mauro ^a   Cimminiello, Claudio ^a  

^a DESIO HOSPITAL   (Italy)

Author keywords

Anticoagulation therapy; Atrial fibrillation; Real life; Warfarin

Indexed keywords

EID: 84894514116     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-12-5     Document Type: Review

References (48)

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131:492-501.
2. Stroke Prevention in Atrial Fibrillation Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994, 343:687-691. Stroke Prevention in Atrial Fibrillation Investigators.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867. 10.7326/0003-4819-146-12-200706190-00007, 17577005.
4. The ACTIVE Writing Group on behalf of the ACTIVE Investigators Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367:1903-1912. The ACTIVE Writing Group on behalf of the ACTIVE Investigators.
5. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E., BAFTA investigators; Midland Research Practices Network (MidReC) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370:493-503. 10.1016/S0140-6736(07)61233-1, 17693178, BAFTA investigators; Midland Research Practices Network (MidReC).
6. Stroke Prevention in Atrial Fibrillation Investigators Stroke prevention in atrial fibrillation study. Final results. Circulation 1991, 84:527-539. Stroke Prevention in Atrial Fibrillation Investigators.
7. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349:1019-1026. 10.1056/NEJMoa022913, 12968085.
8. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Arch Intern Med 2007, 167:239-245. 10.1001/archinte.167.3.239, 17296878.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L., RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151. 10.1056/NEJMoa0905561, 19717844, RE-LY Steering Committee and Investigators.
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM., ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891. 10.1056/NEJMoa1009638, 21830957, ROCKET AF Investigators.
11. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW., et al: ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992. 10.1056/NEJMoa1107039, 21870978, et al: ARISTOTLE Committees and Investigators.
12. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165:1095-1106. 10.1001/archinte.165.10.1095, 15911722.
13. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996, 348:423-428. 10.1016/S0140-6736(96)01109-9, 8709780.
14. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G., Italian Federation of Anticoagulation Clinics Bleeding risk in very Old patients on vitamin K antagonist treatment. Result of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 2011, 124:824-829. 10.1161/CIRCULATIONAHA.110.007864, 21810658, Italian Federation of Anticoagulation Clinics.
15. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Cairo J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007, 23:83-91. 10.1007/s11239-006-9022-7, 17221328.
16. Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 2006, 21:73-77. 10.1007/s11239-006-5580-y, 16475046.
17. Kim YK, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N, Kaatz S, Eikelboom JW. Effect of a simple two-step warfarin dosing algorithm on anticoagulation control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 2009, 8:101-106.
18. Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG. Effect of computer-aidedd management on the quality of treatment n anticoagulated patients: a prospective, randomized, multi center trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica 2001, 86:1060-1070.
19. The Internationl Warfarin Pharmacogenetics Consortium Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360:753-764. 2722908, 19228618, The Internationl Warfarin Pharmacogenetics Consortium.
20. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010, 28:61-74. 10.2165/11318240-000000000-00000, 20014877.
21. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra PL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141(Suppl 1):e152S-e184S. 3278055, 22315259.
22. Bloomfield HE, Krause A, Greer N, Taylor BC, MacDonald R, Rutks I, Reddy P, Wilt TJ. Meta-analysis: Effect of Patient Self-testing and Self-management of Long-Term Anticoagulation on Major Clinical Outcomes. Ann Intern Med 2011, 154:472-482. 10.7326/0003-4819-154-7-201104050-00005, 21464349.
23. Censis. 2012, " La fibrillazione atriale: diffondere le conoscenze e migliorare le cure" Il sole 24 ore.
24. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control. A systematic review and metaregression. Chest 2006, 129:1155-1166. 10.1378/chest.129.5.1155, 16685005.
25. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S., ACTIVE W Investigators Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centres and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037. 10.1161/CIRCULATIONAHA.107.750000, 18955670, ACTIVE W Investigators.
26. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ., RE-LY investigators Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010, 376:975-983. 10.1016/S0140-6736(10)61194-4, 20801496, RE-LY investigators.
27. Degli Esposti L, Sangiorgi D, Di Pasquale G, Gensini GF, Iori I, Buda S, Degli EE. Adherence to treatment and anticoagulation control in vitamin-K antagonists treated-patients: an administrative databases analysis in a large Italian population. Farmeconomia 2011, 12:63-69.
28. Caro JJ, Flegel KM, Orejuela ME, Kelley HE, Speckman JL, Migliaccio-Walle K. Anticoagulation prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. CMAJ 1999, 161:493-497. 1230577, 10497604.
29. Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. CMRO 2005, 21:1583-1594.
30. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation. Stroke 2006, 37:1070-1074. 10.1161/01.STR.0000208294.46968.a4, 16528001.
31. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoaugulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999, 131:927-934.
32. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 2013, 185:E121-E127. 10.1503/cmaj.121218, 3563912, 23184840.
33. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, López-Sendón J, Vardas PE, Aliot E, Santini M, Crijns HJ., Euro Heart Survey Investigators Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006, 27:3018-3026. 10.1093/eurheartj/ehl015, 16731536, Euro Heart Survey Investigators.
34. Di Pasquale G, Mathieu G, Maggioni AP, Fabbri G, Lucci D, Vescovo G, Pirelli S, Chiarella F, Scherillo M, Gulizia MM, Gussoni G, Colombo F, Panuccio D, Nozzoli C, Berisso MZ., on behalf of ATA-AF Investigators Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: The ATA AF Study. Int J Cardiol 2012, Epub ahead of print, on behalf of ATA-AF Investigators.
35. Waldo AL, Becker RC, Tapson VF, Colgan KJ., NABOR Steering Committee Hospitalized patients with atrial fibrillation and a high risk of stroke Are Not being provided with adequate anticoagulation. J Am Coll Cardiol 2005, 46:1729-1736. 10.1016/j.jacc.2005.06.077, 16256877, NABOR Steering Committee.
36. Filippi A, Bettoncelli G, Zaninelli A. Detected atrial fibrillation in North Italy: tares, calculated stroke risk and proportion of patients receiving thrombo-prophylaxis. Fam Pract 2000, 17:337-339. 10.1093/fampra/17.4.337, 10934184.
37. Mazzaglia G, Filippi A, Alacqua M, Cowell W, Shakespeare A, Mantovani LG, Bianchi C, Cricelli C. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost 2010, 103:968-975. 10.1160/TH09-08-0525, 20216987.
38. Rosenman MB, Simon TA, Teal E, McGuire P, Nisi D, Jackson JD. Perceived or actual barriers to warfarin Use in atrial fibrillation based on electronic medical records. Am J Ther 2012, 19:330-337. 10.1097/MJT.0b013e3182546840, 22964558.
39. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999, 159:677-685. 10.1001/archinte.159.7.677, 10218746.
40. Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, Weeke P, Hansen ML, Gislason GH, Torp-Pedersen C. Bleeding risk in 'real world' patients with atrial fibrillation: comparison ot two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011, 9:1460-1467. 10.1111/j.1538-7836.2011.04378.x, 21624047.
41. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR2HAGES, ATRIA and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation. The AMADEUS (evaluating the Use of SR34006 compared to warfarin or Acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012, 60:861-867. 10.1016/j.jacc.2012.06.019, 22858389.
42. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A., et al. ESC Committee for Practice Guidelines (CPG) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012, 33:2719-2747. ESC Committee for Practice Guidelines (CPG).
43. Southworth MR, Reichman ME, Unger EF. Dabigatran and Postmarketing reports of bleeding. N Engl J Med 2013, 368:1272-1274. 10.1056/NEJMp1302834, 23484796.
44. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in " real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013, 61:2264-2273. 10.1016/j.jacc.2013.03.020, 23562920.
45. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L., Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators Newly identified events in the RE-LY trial. N Engl J Med 2010, 363:1875-1876. 10.1056/NEJMc1007378, 21047252, Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators.
46. Dale B, Eikelboom JW, Weitz JI, Young E, Paikin JS, Coppens M, Whitlock RP, Connolly SJ, Ginsberg JS, Hirsh J. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain differential effects on intracranial hemorrhage and myocardial infarction?. J Thromb Thrombolysis 2013, 35:295-301. 10.1007/s11239-012-0857-9, 23242974.
47. Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open 2012, 2:e001592. doi:10.1136/bmjopen-2012-001592, 3488718, 23043126.
48. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011, 365:2002-2012. 10.1056/NEJMsa1103053, 22111719.